Actis Invests US$48 Million in Symbiotec Pharmalab (Asia)

Source: Actis

Pan-emerging markets private equity firm Actis has announced a US$48 million investment for a significant stake in India-based Symbiotec Pharmalab, producer of steroid-hormone active pharmaceutical ingredients. Symbiotec, which produces active ingredients for medicine manufacturers, intends to use the new financing for company growth.